rs4353135 TT | rs4353135 GT | rs4353135 GG | p value (Fisher or Kruskal–Wallis) | |
---|---|---|---|---|
Gender | ||||
Male (n = 369) Female (n = 321) | 169 (53.3%) 148 (46.7%) | 165 (55.2%) 134 (44.8%) | 35 (47.5%) 39 (52.7%) | 0.474 |
Age at diagnosis [years] | ||||
Median, q25–q75, Min–max | 27.4, 19.7–38.4, 3.2–79.6 | 28.7, 20.4–38.4, 2.9–78.1 | 29.3, 19.2–42.6, 3.9–72.1 | 0.628 |
Disease duration [years] | ||||
Median, q25–q75, Min–max | 10.9, 6.9–18.4, 0.3–49.5 | 11.5, 6.9–17.6, 0.2–48.7 | 13.1, 6.9–22.5, 1.0–45.3 | 0.580 |
Complications* | ||||
No (n = 286) Yes (n = 404) | 135 (42.6%) 182 (57.4%) | 125 (41.8%) 174 (58.2%) | 26 (35.1%) 48 (64.9%) | 0.507 |
MTWAI**—maximal value throughout follow-up | ||||
Median, q25–q75, Min–max | 4, 2–9, 0–19 | 5, 2–9, 0–18 | 4, 2–7, 0–14 | 0.129 |
Reported flare* | ||||
No (n = 284) Yes (n = 406) | 121 (38.2%) 196 (61.8%) | 130 (43.5%) 169 (56.5%) | 33 (44.6%) 41 (55.4%) | 0.329 |
Flare possibly or highly related to (focus on yes): | ||||
NSAIDs Antibiotics GI tract infection Other infection Treatment decr./disc Other medication | 11 (5.6%) 4 (2.0%) 32 (16.3%) 23 (11.7%) 50 (25.5%) 4 (2.0%) | 11 (6.5%) 4 (2.4%) 34 (20.1%) 11 (6.5%) 41 (24.3%) 9 (5.3%) | 1 (2.4%) 0 (0%) 8 (19.5%) 5 (12.2%) 7 (17.1%) 1 (2.4%) | 0.705 1.000 0.632 0.168 0.543 0.219 |
Flare management (focus on the yes): | ||||
Hospitalization Ambulatory Surgery Drug therapy | 24 (12.2%) 67 (34.2%) 8 (4.1%) 178 (90.8%) | 20 (11.8%) 30 (17.8%) 10 (5.9%) 150 (88.8%) | 2 (4.9%) 7 (17.1%) 1 (2.4%) 40 (97.6%) | 0.443 0.001 0.692 0.248 |
Focus on the hospitalizations: | ||||
Total days of hosp. Median, q25–q75, Min–max | 6.5, 2.5–18.5, 0–90 | 0, 0–7, 0–41 | 3, 0–6, 0–6 | 0.038 |